In Chugai Seiyaku Kabushiki Kaisha and Hoffmann-La Roche AG v Frensenius Kabi Oncology Limited and Fresensius Kabi India Private Limited, the plaintiff, Chugair Seiyaku Kabushiki Kaisha (CSKK) sought a permanent injunction against Fresenius Kabi Oncology Limited (FKOL) and Fresensius Kabi India Private Limited for infringing its Indian patent protecting Alectinib, an oral drug used to treat a certain type of non-small-cell lung cancer.
CSKK and its exclusive licencee, Hoffmann-La Roche, contended that, in May 2021, FKOL imported Alectinib and exported Alectinib hydrochloride. CSKK further contended that an independent online investigation revealed various online listings of FKOL for a generic version of Alectinib on the Pharma Compass and Chemical Book websites.
